Pancreatic Cancer Research

ResearcherTUM KlinikumActive in the last 2 years

Richard A Hubner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7081-8823; OpenAlex author ID A5075059160. Sources: OpenAlex.

Their work

Papers
29 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
83
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 3 papers · 2017: 4 papers · 2018: none · 2019: 6 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 4 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 29

  1. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Co-author DOI 10.1016/j.esmoop.2025.106043↗
  2. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… Co-author DOI 10.1016/j.esmoop.2026.108307↗
  3. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… Co-author DOI 10.1016/j.esmoop.2025.105534↗
  4. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Co-author DOI 10.1080/14796694.2025.2458458↗
  5. Systemic Therapy for Metastatic Pancreatic Cancer-Current Landscape and Future Directions. Last author DOI 10.3390/curroncol31090385↗
  6. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  7. Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15030738↗
  8. Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy … Co-author DOI 10.3390/cancers15082277↗
  9. Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre. Co-author DOI 10.3390/healthcare11202802↗
  10. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2022.02.014↗
  11. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemothera… Co-author DOI 10.1080/0284186x.2022.2053198↗
  12. Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy … Co-author DOI 10.1136/bmjopen-2020-042067↗
  13. The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer. Co-author DOI 10.3390/cancers13153779↗
  14. Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.09.012↗
  15. The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001486↗
  16. Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. First author DOI 10.1002/jso.25440↗
  17. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Co-author DOI 10.1016/j.ejca.2018.09.029↗
  18. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. First author DOI 10.1016/j.ejca.2018.12.007↗
  19. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Co-author DOI 10.1016/j.pan.2018.10.003↗
  20. Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Co-author DOI 10.1038/s41598-019-47489-7↗
  21. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. Co-author DOI 10.4251/wjgo.v11.i2.102↗
  22. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing … Co-author DOI 10.1007/s10637-017-0473-9↗
  23. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based … Last author DOI 10.1038/bjc.2017.67↗
  24. Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations. Co-author DOI 10.1200/jco.2016.70.1607↗
  25. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/ijms18050909↗
  26. 18F-FLT PET imaging of cellular proliferation in pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2015.12.014↗
  27. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-con… Co-author DOI 10.1016/j.ctrv.2016.09.001↗
  28. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  29. Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e31826c6aee↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mairead Geraldine McNamara · 15 shared papers, 2016–2024 · strength 2.03
  2. Juan W. Valle · 15 shared papers, 2016–2023 · strength 1.85
  3. Ángela Lamarca · 14 shared papers, 2016–2023 · strength 1.73
  4. Davide Melisi · 7 shared papers, 2017–2026 · strength 1.14
  5. Teresa Mercade Macarulla · 6 shared papers, 2017–2026 · strength 1.05
  6. Zev A. Wainberg · 5 shared papers, 2023–2026 · strength 0.99
  7. Eileen Mary O'Reilly · 5 shared papers, 2023–2026 · strength 0.99
  8. Andrew Scott Paulson · 5 shared papers, 2023–2026 · strength 0.99
  9. Roberto Pazo-Cid · 5 shared papers, 2023–2026 · strength 0.99
  10. Tanios Bekaii‐Saab · 5 shared papers, 2023–2026 · strength 0.99
  11. Shubham Pant · 5 shared papers, 2023–2026 · strength 0.99
  12. Eric Van Cutsem · 5 shared papers, 2023–2026 · strength 0.99
  13. Sreenivasa Rao Chandana · 3 shared papers, 2023–2025 · strength 0.54
  14. Thorsten Oliver Goetze · 3 shared papers, 2023–2025 · strength 0.54
  15. Christelle de la Fouchardière · 3 shared papers, 2023–2025 · strength 0.54
  16. Igor Kišš · 3 shared papers, 2023–2025 · strength 0.54
  17. Rille Pihlak · 4 shared papers, 2017–2023 · strength 0.48
  18. Hassan A. Hatoum · 2 shared papers, 2026 · strength 0.46
  19. Vincent M. Chung · 2 shared papers, 2026 · strength 0.46
  20. Lindsay E. Carnie · 3 shared papers, 2020–2023 · strength 0.42
  21. Andrew Peter Dean · 2 shared papers, 2023–2025 · strength 0.34
  22. Li‐Tzong Chen · 4 shared papers, 2017–2019 · strength 0.32
  23. Jens Thomas Siveke · 4 shared papers, 2017–2019 · strength 0.32
  24. Andrea Wang‐Gillam · 4 shared papers, 2017–2019 · strength 0.32
  25. Daniel D. Von Hoff · 4 shared papers, 2017–2019 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.